NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins

Concepts

• immunoglobulins
• leeds
• anti-d immunoglobulins
• licenced human albumin solution
• normal
• albumin solution & normal
• licenced
• human
• anti
• albumin

Location

Framework intended for use by the NHS in England, Northern Ireland, Scotland. The agreement may also be used by private sector contractors and agents working on behalf of the above.

Description

This market engagement relates to the NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins. The framework is anticipated to commence on 1 January 2025 for a period of 36 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. Total maximum framework agreement including extension options will be no more than 48 months. The purpose of the PIN is to engage with the supply market on the procurement approach and to understand market and supplier capacities prior to the Invitation to Tender.

CPV Codes

• 33651520 - Immunoglobulins

Indicators

Other Information

Total maximum framework agreement including extension options will be no more than 48 months. The purpose of the PIN is to engage with the supply market on the procurement approach and to understand market and supplier capacities prior to the Invitation to Tender. The market engagement documents will be made available during March for unrestricted and full direct access, free of charge, at http://health.atamis.co.uk under project reference C228466.Please be aware the NHSE principal address has changed to Wellington House 133-155 Waterloo Road London SE1 8UG